Abstract
Daunomycin is a potent inducer of p53 and NF-κB transcription factors. It is also able to increase the amount of the p21 cyclin-dependent kinase inhibitor. The human p21 promoter harbors p53-responsive elements and an NF-κB binding site. We demonstrated, in human breast and colon carcinoma cells, the binding of NF-κB dimers to the κB site and the transcriptional activation of the human p21 promoter by daunomycin and by NF-κB subunits, thereby confirming the functionality of this κB binding site. However, using different tumor cell lines where p53 or NF-κB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-κB-independent, whereas daunomycin-induced apoptosis was p53- and NF-κB-independent.
Footnotes
-
Send reprint requests to: M.-P. Merville, Medical Chemistry, Pathology B23, Sart-Tilman, 4000 Liège, Belgium. E-mail: mpmerville{at}ulg.ac.be
-
↵1 This research was supported by grants from Télévie, the National Fund for Scientific Research, and the “Centre Anti-Cancéreux” (University of Liège, Belgium). A.-C.H. is a Research Assistant at the National Fund for Scientific Research (Belgium). V.Bo. is a Senior Research Associate and M.-P.M. is a Research Associate at the National Fund for Scientific Research (Belgium).
- Abbreviations:
- Cdk
- cyclin-dependent kinase
- WAF1
- wild-type p53-activated factor 1
- CIP1
- Cdk-interacting protein 1
- Gadd
- growth arrest and DNA damage
- STAT
- signal transducers and activators of transcription
- NF-κB
- nuclear factor-κB
- CMV
- cytomegalovirus
- HPV-16
- human papillomavirus type 16
- NAC
- N-acetylcysteine
- IκBα
- inhibitor κB α
- PDTC
- pyrrolidine-9-dithiocarbamate
- LUC
- luciferase
- CAT
- chloramphenicol acetyltransferase
- EMSA
- electrophoretic mobility shift assay
- FACS
- fluorescence-activated cell-sorting analysis
- RSV
- rous sarcoma virus
- ATCC
- American Type Culture Collection
- WST-1
- 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate
- OCT
- octamer binding protein
- Received May 18, 2000.
- Accepted August 2, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
